Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: rokoko who wrote (933)	10/7/2004 1:16:35 AM
From: tuck	Read Replies (1) \| Respond to of 3557

OT: feel free to enlighten us to your TA take on TELK on that thread: Subject 37044 Recent trial results seem fine, but the stock has sold off a bit. Perhaps investors are seeing only the additional burn because TELK announced another PIII based on one of those PII results. Given that companies like NBIX were also thorough in trialing their compounds and have been rewarded, why is the Street being stingy with TELK? Seems unjust to me, but a trading op, perhaps, as MZ suggested elsewhere in response to you. TIA & Cheers, Tuck